Florbetaben
Phase 1Small molecule
Florbetaben is one of 175 small molecule programs targeting Cognitive impairment. It is currently in Phase 1.
5
Indications
12
Total Trials
3
Active Trials
174
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Florbetaben
LLife Molecular Imaging GmbH
Phase 1
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alzheimer's Disease4 trials
Imaging Inflammation in Alzheimer's Disease With 11C-ER176
Completed·—·Phase 1/2·NCT03744312·9 enrolled
Show 1 more trial
AL amyloidosis2 trials
Phase II2 trials
Cardiotoxicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Florbetaben. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLife Molecular Imaging GmbH